| Product Name |
Recombinant Human Tumor Necrosis Factor Receptor Superfamily, Member 5 (CD40) Protein |
| Product Overview |
This recombinant human Tumor Necrosis Factor Receptor Superfamily, Member 5 (CD40) protein includes amino acids 26-187aa of the target gene is expressed in E.coli.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization. |
| Target Uniprot Id |
P25942 |
| Recommended Name |
Tumor necrosis factor receptor superfamily member 5 |
| Gene Name |
CD40 |
| Synonyms |
CD40 molecule, TNF receptor superfamily member 5, Bp50, CDW40, p50, TNFRSF5 |
| Species |
Human |
| Predicted Molecular Mass |
22 kDa |
| Expression System |
E.coli |
| Expression Range |
26-187aa |
| Tag |
N-6His |
| Purity |
>95% |
| Formulation |
Lyophilized |
| Buffer |
Phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose |
| Storage Condition |
1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C. |
| Reconstitution Instruction |
Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%. |
| Applications |
Positive Control; Immunogen; SDS-PAGE; WB |
| Research Area |
Immunology |
| Target Function |
Receptor for TNFSF5/CD40LG. Transduces TRAF6- and MAP3K8-mediated signals that activate ERK in macrophages and B cells, leading to induction of immunoglobulin secretion. |
| Subcellular Location |
[Isoform I]: Cell membrane; Single-pass type I membrane protein.; [Isoform II]: Secreted. |
| Associated Diseases |
Immunodeficiency with hyper-IgM 3 (HIGM3) |
| Tissue Specificity |
B-cells and in primary carcinomas. |
